Copyright
©The Author(s) 2015.
World J Pharmacol. Mar 9, 2015; 4(1): 96-116
Published online Mar 9, 2015. doi: 10.5497/wjp.v4.i1.96
Published online Mar 9, 2015. doi: 10.5497/wjp.v4.i1.96
Figure 4 Mechanisms of multidrug resistance in cancer cells.
(1) Active drug efflux by drug transporters, such as Pgp, multidrug resistance-associated protein, and breast cancer resistance protein; (2) Loss of cell surface receptors and/or drug transporters or alterations in membrane lipid composition; (3) Compartmentalization of the drug in cellular vesicles; (4) Altered/increased drug targets; (5) Alterations in cell cycle; (6) Increased drug metabolism/enzymatic inactivation; (7) Active damage repair; and (8) Inhibition of apoptosis. Reprinted with permission from ref. [181].
- Citation: Cuestas ML, Oubiña JR, Mathet VL. Hepatocellular carcinoma and multidrug resistance: Past, present and new challenges for therapy improvement. World J Pharmacol 2015; 4(1): 96-116
- URL: https://www.wjgnet.com/2220-3192/full/v4/i1/96.htm
- DOI: https://dx.doi.org/10.5497/wjp.v4.i1.96